Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical pharmacology and therapy

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/clpt.2011.164PMID 21937987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral® Formulation

  2012cited by this paper
• Deaths involving contraindicated and inappropriate combinations of serotonergic drugs

  2011cited by this paper
• Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam

  2010cited by this paper
• Assessment of oral midazolam limited sampling strategies to predict area under the concentration time curve (AUC) during cytochrome P450 (CYP) 3A baseline, inhibition and induction or activation.

  2010cited by this paper
• Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity

  2010cited by this paper
• Effect of Different Durations of Ketoconazole Dosing on the Single‐Dose Pharmacokinetics of Midazolam: Shortening the Paradigm

  2009cited by this paper
• Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

  2008cited by this paper
• Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A‐Mediated Drug Interactions

  2008cited by this paper
• Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A

  2008cited by this paper
• Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

  2008cited by this paper
• The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly

  2007cited by this paper
• Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in Humans

  2007cited by this paper
• Admissions to a medical intensive care unit related to adverse drug reactions.

  2007cited by this paper
• Limited Sampling Models for Oral Midazolam: Midazolam Plasma Concentrations, Not the Ratio of 1‐Hydroxymidazolam to Midazolam Plasma Concentrations, Accurately Predicts AUC as a Biomarker of CYP3A Activity

  2006cited by this paper
• Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir

  2006cited by this paper
• Single‐point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam

  2005cited by this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cited by this paper
• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  2004cited by this paper
• C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.

  2004cited by this paper
• Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice

  2003cited by this paper
• Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

  2002cited by this paper
• Hospital Admissions Resulting from Preventable Adverse Drug Reactions

  2002cited by this paper
• Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers

  2001cited by this paper
• Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.

  2000cited by this paper
• Measuring agreement in method comparison studies

  1999cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

  1997cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996cited by this paper
• What happens to long-term medication when general practice patients are referred to hospital?

  1996cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995cited by this paper
• Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

  1994cited by this paper
• Cellular transport and accumulation of thiotepa in murine, human, and avian cells.

  1989cited by this paper
• Pharmacokinetics of midazolam in anaesthetized cirrhotic patients.

  1988cited by this paper
• Limited sampling model for vinblastine pharmacokinetics.

  1987cited by this paper

• Limited Sampling Strategy of Rosuvastatin Single-Time-point Concentrations Accurately Estimate Exposure and Constitutive Transporter Activities in Healthy Adults.

  2025cites this paper
• FORMULATION DEVELOPMENT AND PHARMACOKINETIC STUDIES OF NIRMATRELVIR LOADED SOLID LIPID NANOPARTICLES USING BOX-BEHNKEN DESIGN

  2025cites this paper
• Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers

  2025cites this paper
• Clozapine and nirmatrelvir/ritonavir coadministration without apparent interaction in a patient with mild COVID-19 infection: A case with review of other clozapine-related CYP3A4 interactions.

  2025cites this paper
• Pharmacokinetics of dexamethasone in tuberculosis meningitis

  2025cites this paper
• Pharmacokinetics of Dexamethasone in Tuberculous Meningitis.

  2025cites this paper
• Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China

  2025cites this paper
• A case report of drug–drug interaction between voriconazole and simnotrelvir/ritonavir

  2025cites this paper
• The Effects of Ritonavir on the Pharmacokinetics of Tofacitinib in Rats

  2025cites this paper
• Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs

  2025cites this paper
• Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin

  2024influential citation
• Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection.

  2024cites this paper
• Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies

  2024influential citation
• Novel approaches for preventing COVID-19 infection in immunocompromised patients with hematologic malignancies

  2024cites this paper
• Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms

  2024cites this paper
• Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19

  2024cites this paper
• An open‐label study to explore the optimal design of CYP3A drug–drug interaction clinical trials in healthy Chinese people

  2024cites this paper
• Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function

  2024cites this paper
• Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.

  2024cites this paper
• The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review

  2024cites this paper
• Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review

  2024cites this paper
• Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19

  2024cites this paper
• Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

  2024cites this paper
• Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort

  2024cites this paper
• A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

  2024cites this paper
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers

  2023cites this paper
• Elevated Tacrolimus Blood Concentration Due to the Interaction with Nirmatrelvir/Ritonavir During COVID-19 Treatment: A Case Report

  2023cites this paper
• Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach

  2023influential citation
• Individual Dose Recommendations for Drug Interaction Between Tacrolimus and Voriconazole in Adult Liver Transplant Recipients: A Semiphysiologically Based Population Pharmacokinetic Modeling Approach.

  2023cites this paper
• Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin

  2023influential citation
• Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers

  2023cites this paper
• Plasma 6β‐hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method

  2023cites this paper
• [Translated article] Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to DDIs.

  2023cites this paper
• Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

  2023cites this paper
• Strategies to Mitigate the Drug-Drug Interaction between Nirmatrelvir/Ritonavir and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Azole Antifungals: Results of a Case Series

  2023cites this paper
• Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to drug-drug interactions.

  2023cites this paper
• Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.

  2023cites this paper
• A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.

  2023cites this paper
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins

  2023influential citation
• Danazol increases the oral bioavailability of midazolam by inactivation of hepatic and intestinal CYP3A in rats

  2023cites this paper
• Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data

  2023cites this paper
• Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir

  2023cites this paper
• Gestion de l'interaction entre le tacrolimus et le nirmatrelvir/ritonavir dans le traitement de la COVID-19 en transplantation d'organe solide.

  2023cites this paper
• An update on drug-drug interactions for care of the acutely ill in the era of COVID-19

  2023cites this paper
• Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child)

  2023cites this paper
• SIOG COVID-19 working group recommendations on COVID-19 therapeutic approaches in older adults with cancer

  2023cites this paper
• Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults

  2023cites this paper
• Case Report: tacrolimus toxicity in the setting of concurrent Paxlovid use in a heart-transplant recipient

  2023cites this paper
• Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

  2023cites this paper
• Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware

  2022cites this paper
• Nirmatrelvir/ritonavir use: Managing clinically significant drug‐drug interactions with transplant immunosuppressants

  2022cites this paper
• Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans

  2022cites this paper
• PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19.

  2022cites this paper
• Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

  2022cites this paper
• Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

  2022cites this paper
• Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal

  2022cites this paper
• New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19

  2022cites this paper
• Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs

  2022cites this paper
• Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy

  2022cites this paper
• Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19

  2022cites this paper
• The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

  2022cites this paper
• A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.

  2022cites this paper
• Managing Covid-19 in patients with heart failure: current status and future prospects

  2022cites this paper
• Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion

  2022cites this paper
• Ritonavir-Boosted Nirmatrelvir (Paxlovid)

  2022cites this paper
• Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study

  2022cites this paper
• Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series

  2022cites this paper
• Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir.

  2022cites this paper
• Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID‐19 in solid organ transplant recipients

  2022cites this paper
• Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail

  2021cites this paper
• Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate

  2021cites this paper
• Myopathy, residual effect of rocuronium, or both? A possible ritonavir–rocuronium interaction interfering weaning from mechanical ventilation in a patient with COVID-19 pneumonia

  2021cites this paper
• Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity

  2020cites this paper
• Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models

  2020cites this paper
• Midazolam microdosing applied in early clinical development for drug–drug interaction assessment

  2020cites this paper
• Proposal of a Safe and Effective Study Design for CYP3A‐Mediated Drug‐Drug Interactions

  2020cites this paper
• Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs

  2020cites this paper
• Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.

  2020cites this paper
• Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial

  2020cites this paper
• Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity

  2020cites this paper
• Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies

  2019cites this paper
• 4β‐Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation

  2019cites this paper
• Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug–Drug Interactions with Potential Perpetrator Drugs

  2019cites this paper
• Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.

  2019cites this paper
• Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A

  2019cites this paper
• A follow‐up report on potential drug interactions with clementines: Two single case experiments show no effect on CYP3A‐dependent midazolam clearance

  2019cites this paper
• Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients

  2019cites this paper
• A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development

  2019cites this paper
• Prolonged‐Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers

  2019cites this paper
• Planning and Assessment of Bioequivalence Studies of Darunavir Preparations

  2018cites this paper
• In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective Trial

  2018cites this paper
• Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

  2018cites this paper
• Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients

  2017cites this paper
• Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics

  2017cites this paper
• Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity

  2017cites this paper
• Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice

  2017cites this paper